Evidence map›Paper›PMID 30323955›Full record

ReviewNPJ vaccines2018

Cell culture-derived influenza vaccines in the severe 2017-2018 epidemic season: a step towards improved influenza vaccine effectiveness.

Ian G Barr, Ruben O Donis, Jacqueline M Katz, John W McCauley, Takato Odagiri, Heidi Trusheim, Theodore F Tsai, David E Wentworth

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in NPJ vaccines, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 64 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
64citing papers in PubMed, 1 pooled it
10.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

64 citing papers in PubMed, 1 synthesis or guideline pooled it, 114 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Article
  5. Review
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Review
  20. Article

4 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 7 institutions in 5 countries.

Ian G Barr1WHO Collaborating Centre for Reference and Research on Influenza, The Peter Doherty Institute For Infection And Immunity, 792 Elizabeth Street, Melbourne, 3000 Australia.
Ruben O DonisBiomedical Advanced Research and Development Authority, Influenza and Emerging Infectious Diseases Division, 300 Independence Avenue, SW, Washington, DC 20201 USA.
Jacqueline M Katz3Influenza Division, Centers for Disease Control and Prevention (CDC), 1600 Clifton Road MS A-20, Atlanta, GA 30329-4027 USA.
John W McCauley4WHO Collaborating Centre for Reference and Research on Influenza, Crick Worldwide Influenza Centre, The Francis Crick Institute, 1, Midland Road, London, NW1 1AT UK.
Takato OdagiriWHO Collaborating Centre for Reference and Research on Influenza, National Institute of Infectious Diseases, Influenza Virus Research Center, 4-7-1 Gakuen, Musashi-Murayama-shi, Tokyo 208-0011 Japan.
Heidi TrusheimIDT Biologika GmbH, Am Pharmapark, 06861 Dessau-Rosslau, Germany.
Theodore F Tsai7Takeda Vaccines (USA), 75 Sidney St, Cambridge, MA 02139 USA.
David E Wentworth8Influenza Division, Centers for Disease Control and Prevention (CDC), 1600 Clifton Road MS A-20, Atlanta, GA 30329-4027 USA.
Centers for Disease Control and Prevention · USBiomedical Advanced Research and Development Authority · USIDT Biologika (Germany) · DENational Institute of Infectious Diseases · JPPeter Doherty Institute · AUTakeda (United States) · USThe Francis Crick Institute · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The 2017-2018 seasonal influenza epidemics were severe in the US and Australia where the A(H3N2) subtype viruses predominated. Although circulating A(H3N2) viruses did not differ antigenically from that recommended by the WHO for vaccine production, overall interim vaccine effectiveness estimates were below historic averages (33%) for A(H3N2) viruses. The majority (US) or all (Australian) vaccine doses contained multiple amino-acid changes in the hemagglutinin protein, resulting from the necessary adaptation of the virus to embryonated hen's eggs used for most vaccine manufacturing. Previous reports have suggested a potential negative impact of egg-driven substitutions on vaccine performance. With BARDA support, two vaccines licensed in the US are produced in cell culture: recombinant influenza vaccine (RIV, Flublok™) manufactured in insect cells and inactivated mammalian cell-grown vaccine (ccIIV, Flucelvax™). Quadrivalent ccIIV (ccIIV4) vaccine for the 2017-2018 influenza season was produced using an A(H3N2) seed virus propagated exclusively in cell culture and therefore lacking egg adaptative changes. Sufficient ccIIV doses were distributed (but not RIV doses) to enable preliminary estimates of its higher effectiveness relative to the traditional egg-based vaccines, with study details pending. The increased availability of comparative product-specific vaccine effectiveness estimates for cell-based and egg-based vaccines may provide critical clues to inform vaccine product improvements moving forward.

Identifiers

PMID30323955
PMCPMC6177469
OpenAlexW2889891640

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.